- Conditions
- Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma
- Interventions
- dexamethasone, vincristine sulfate, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, teniposide, vinblastine, natural killer cell infusion, laboratory biomarker analysis, therapeutic hydrocortisone, allogeneic hematopoietic stem cell transplantation, CliniMACS
- Drug · Biological · Other + 2 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 3
- States / cities
- San Diego, California • Memphis, Tennessee • Fort Worth, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 176
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Cancer
- Interventions
- filgrastim, mitoxantrone hydrochloride
- Biological · Drug
- Lead sponsor
- Hope Cancer Institute, Inc.
- Industry
- Eligibility
- Male only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Pharmacological Study, Radiation Therapy, Therapeutic Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 31 Years
- Enrollment
- 669 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 166
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 135 more
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia
- Interventions
- Ara-C, Mitoxantrone, Etoposide
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Leukemia, Lymphoma
- Interventions
- filgrastim, pegfilgrastim, rituximab, sargramostim, cyclophosphamide, mitoxantrone hydrochloride, pentostatin, fluorescence in situ hybridization, gene rearrangement analysis, polymerase chain reaction, protein expression analysis, flow cytometry, biopsy
- Biological · Drug · Genetic + 2 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Etoposide Phosphate, Mitoxantrone Hydrochloride, Multigated Acquisition Scan, Peposertib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 15
- States / cities
- Duarte, California • Los Angeles, California • Newport Beach, California + 11 more
- Conditions
- Leukemia, Acute Myeloid (AML)
- Interventions
- gilteritinib, LoDAC (Low Dose Cytarabine), Azacitidine, MEC (Mitoxantrone, Etoposide, Cytarabine), FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 28 more
- Conditions
- Leukemia
- Interventions
- filgrastim, cladribine, cytarabine, etoposide, methotrexate, mitoxantrone hydrochloride, therapeutic hydrocortisone, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2008
- U.S. locations
- 35
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 27 more
- Conditions
- Leukemia, Myelocytic, Acute
- Interventions
- Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 8
- States / cities
- Palo Alto, California • Boston, Massachusetts • Detroit, Michigan + 4 more
- Conditions
- Acute Myeloid Leukemia, Myeloid Neoplasm
- Interventions
- Liposome-encapsulated Daunorubicin-Cytarabine, Cladribine, Cytarabine, Recombinant Granulocyte Colony-Stimulating Factor, Mitoxantrone, Questionnaire Administration, Quality-of-Life Assessment
- Drug · Biological · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Interventions
- Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Venetoclax
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Boston, Massachusetts
- Conditions
- Acute Myeloid Leukemia, Leukemia Cutis, Myeloid Neoplasm, Myeloid Sarcoma
- Interventions
- Asparaginase, Bortezomib, Cytarabine, Daunorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration, Sorafenib Tosylate
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 29 Years
- Enrollment
- 1,645 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2026
- U.S. locations
- 195
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
- Interventions
- cabozantinib, mitoxantrone, prednisone
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 49
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 42 more
- Conditions
- Ovarian Cancer
- Interventions
- mitoxantrone hydrochloride, thiotepa, topotecan hydrochloride, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2001
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Malignant Neoplasm, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia
- Interventions
- alvocidib, cytarabine, mitoxantrone hydrochloride, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Madison, Wisconsin
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
- Interventions
- Crenolanib, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF
- Drug
- Lead sponsor
- Arog Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 9
- States / cities
- Sacramento, California • Gainesville, Florida • Chicago, Illinois + 4 more
- Conditions
- Acute Lymphoblastic Leukemia, Precursor B-Cell Lymphoblastic Leukemia, Precursor T-Cell Lymphoblastic Leukemia
- Interventions
- Decitabine, Vorinostat, Vincristine, Dexamethasone, Mitoxantrone, Pegaspargase, Methotrexate
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 25
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 20 more
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitts Leukemia/Lymphoma, Chronic Myelogenous Leukemia
- Interventions
- CLAG-M
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Valhalla, New York
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- mitoxantrone hydrochloride, ixabepilone, prednisone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 2
- States / cities
- San Francisco, California • Madison, Wisconsin
- Conditions
- Prostate Cancer
- Interventions
- leflunomide, mitoxantrone hydrochloride, prednisone
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 3
- States / cities
- Boca Raton, Florida • Fort Myers, Florida • New York, New York
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoblastic Lymphoma, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma/Leukemia
- Interventions
- Clofarabine, Mitoxantrone
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 2
- States / cities
- Valhalla, New York • Charlotte, North Carolina
- Conditions
- Prostate Cancer
- Interventions
- docetaxel, estramustine, mitoxantrone, prednisone
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 770 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 13 more
- Conditions
- Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia
- Interventions
- 6,8-Bis(benzylthio)octanoic Acid, Cytarabine, Hematopoietic Cell Transplantation, Mitoxantrone Hydrochloride
- Drug · Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
- Interventions
- Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tretinoin
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2029
- U.S. locations
- 152
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more